We are not suggesting that downmodulation of Siglec‐10 from the surface of human CLL cells is mechanistically involved in the development of CLL, but the parallel data from Siglec‐G in the mouse CLL model suggest that downmodulation of this inhibitory receptor may support the maintenance or severity of the disease. The gene discussed is SIGLEC10; the disease is B-cell chronic lymphocytic leukemia.